Joseph Schwartz, an analyst from Leerink Partners, reiterated the Buy rating on Crinetics Pharmaceuticals. The associated price target remains the same with $80.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Joseph Schwartz has given his Buy rating due to a combination of factors that highlight Crinetics Pharmaceuticals’ promising future. The company is on track for the PDUFA action date for Palsonify, a treatment for acromegaly, set for September 25, 2025. This potential approval is a significant milestone, and the company is preparing for its first commercial launch, which includes building infrastructure and raising awareness among healthcare providers and patients.
Additionally, Crinetics is actively engaging with payers and has multiple late-stage programs in progress, including Phase 3 trials for paltusotine in carcinoid syndrome and atumelnant for congenital adrenal hyperplasia. The company’s strategic initiatives and ongoing clinical trials position it as a high-quality investment opportunity. The anticipated launch in Europe in 2026, pending approval, further supports the positive outlook, making Crinetics a compelling buy recommendation.
In another report released yesterday, Citizens JMP also maintained a Buy rating on the stock with a $86.00 price target.
CRNX’s price has also changed moderately for the past six months – from $34.930 to $27.380, which is a -21.61% drop .